TrialClinical cancer research : an official journal of the American Association for Cancer Research2020

A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma.

Irene M Ghobrial et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.